Efficacy, Safety, and Tolerability Topical Nasal Spray in the Prevention of SARS-CoV-2 Infection in Healthcare Personnel

Site Image

Study Overview

The purpose of this study is to assess the effectiveness, safety, and tolerability of GLS-1200 to prevent SARS-CoV-2 infection in healthcare personnel. GLS-1200 contains quinine diluted in saline (salt water). Pre-clinical studies have shown that quinine stimulates nasal cells to secrete compounds that may prevent growth of bacteria and reduce viruses from reproducing. 

Study Description

Treatment: Participants will be randomized to either quinine or placebo group (saline or salt water) at a 2:1 ratio. 
 Duration of the Study: Participants will self-administer study drug three times daily (TID) for 4 weeks. A follow-up visit will be made at 6 weeks to assess participant health since some cases of SARS-CoV-2 infection may not be apparent until after the treatment period has ended.

Click below to see if you may be eligible:
 

  • Study Identifier: 843133

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu